Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
In immunoglobulin A nephropathy (IgAN), absolute proteinuria reduction is a key surrogate biomarker for improved kidney outcomes. The Kidney Disease: Improving Global Outcomes (KDIGO) 2025 guidelines for IgAN recommend absolute proteinuria of <0.5 g/day as a treatment goal (guidelines available at the initiation NefIgArd trial recommended an absolute proteinuria target of <1.0 g/day). Durable proteinuria reductions were observed in NefIgArd, a Phase 3 trial of nefecon in IgAN, with a mean urine protein−creatinine ratio (UPCR) reduction of 51.3% from baseline with nefecon at 12 months. This subanalysis aimed to assess UPCR response at 12 months in patients with IgAN from the NefIgArd trial.
Patients were randomized 1:1 to 16 mg/day nefecon (n=182) or placebo (n=182) for 9 months, followed by 15 months off treatment; optimized supportive care was maintained throughout. Patients were classified by absolute UPCR response at 12 months: ≤0.3, ≤0.5, ≤1, or >1 g/gram.
At 12 months, 65.4% of patients had a UPCR ≤1 g/gram with nefecon vs 33.0% with placebo, 34.6% vs 10.4% of patients had a UPCR ≤0.5 g/gram, and 18.1% vs 4.9% had a UPCR ≤0.3 g/gram. Nefecon-treated patients with a UPCR ≤1 g/gram had a smaller estimated glomerular filtration rate (eGFR) change than patients with >1 g/gram (mean [± standard error] absolute change from baseline at 12 months: 0.11 [–0.70, 0.93] and –4.82 [–6.30, –3.35] mL/min/1.73 m2, respectively).
In the NefIgArd trial, two-thirds of patients achieved an absolute UPCR ≤1 g/gram at 12 months, after 9 months of nefecon treatment and 3 months off treatment. Lower UPCR at 12 months translated into eGFR benefit, demonstrating the disease-modifying effect of nefecon in patients with IgAN.
